Characterization of the Mechanisms of Resistance to Azacitidine

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Centre Hospitalier Universitaire de Nice
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice Identifier:
First received: September 27, 2010
Last updated: May 30, 2016
Last verified: May 2016

Myelodysplastic syndromes (MDS) are frequent diseases in elderly patients (median age: 71 years). IPSS classification defines low risk (Low and Intermediate 1), and high risk (Intermediate 2 and High) MDS. High-risk MDS (MDS-HR) have a high risk of transformation into acute leukemia with multilineage dysplasia (AML-DML). The success of Azacitidine has been mainly achieved through a rigorous empirical and clinical research, but the molecular mechanisms by which this molecule exerts its effects remain poorly characterized. The primary mode of action of Azacytidine is through DNA demethylation, and integration in to mRNA that favor traduction inhibition. The impact of this molecule on various cell death programs involved in the elimination of leukemic cells : apoptosis and autophagy is currently poorly known.

The research program and clinical studies we proposed focus on two major aspects:

- Main objective: Molecular mechanism of action and resistance to Azacitidine: Role of apoptosis versus autophagy.

- Secondary Objective: Reversion of Azacytidine resistance using different drugs targeting apoptosis and/or autophagy. Our laboratory has identified new molecules to selectively induce different types of cell death (apoptosis or autophagy).

Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire de Nice:

Biospecimen Retention:   Samples With DNA
bone marrow samples

Estimated Enrollment: 90
Study Start Date: September 2010
Estimated Study Completion Date: September 2018
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with myelodysplastic syndromes or acute myeloid leukemia with multilineage dysplasia treated with Azacitidine

Inclusion Criteria:

  • Age ≥ 18 years
  • High Risk or Intermediate 2 MDS (IPSS)
  • AML-MD (WHO classification)
  • Treatment with minimum three to six cycles of Azacitidine
  • Informed consent form signed

Exclusion Criteria:

  • Treatment with others chemotherapies alone or in association
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01210274

CHU de Nice - Hôpital de l'Archet Recruiting
Nice, France, 06200
Contact: Thomas Cluzeau, PH   
Principal Investigator: Jill Pa Cassuto, PU-PH         
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Centre Hospitalier Universitaire de Nice Identifier: NCT01210274     History of Changes
Other Study ID Numbers: 10-PP-10 
Study First Received: September 27, 2010
Last Updated: May 30, 2016
Health Authority: France: French Data Protection Authority

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors processed this record on July 27, 2016